Michael Feldhaus

USPTO Granted Patents = 29 (Patent Applications = 18)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 4.7

ph-index = 7

Forward Citations = 187(Granted Patents)

Location History:

Belmont, MA (US) (2014)
Grantham, NH (US) (2010 - 2022)
Boston, MA (US) (2021 - 2024)
Lebanon, NH (US) (2021 - 2024)

Company Filing History:

Merrimack Pharmaceuticals, Inc.

Torque Therapeutics, Inc.

patents

6. 1 out of 45

Celldex Therapeutics Limited

patents

where one patent can have more than one assignee

Years Active: 2010-2024

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12071480 - CD47 antibodies and uses thereof for treating cancer (2024-08-27),

2. 12018403 - Antibody libraries (2024-06-25),

3. 11767365 - BCMA antibodies and use of same to treat cancer and immunological disorders (2023-09-26),

4. 11746160 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2023-09-05),

5. 11471490 - T cells surface-loaded with immunostimulatory fusion molecules and uses thereof (2022-10-18),

6. 11180552 - CD47 antibodies and uses thereof for treating cancer (2021-11-23),

7. 11091559 - Anti-ALK antibodies and methods for use thereof (2021-08-17),

8. 11078291 - BCMA antibodies and use of same to treat cancer and immunological disorders (2021-08-03),

9. 11008568 - Rationally designed, synthetic antibody libraries and uses therefor (2021-05-18),

10. 11008403 - Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use (2021-05-18),

11. 11008383 - Rationally designed, synthetic antibody libraries and uses therefor (2021-05-18),

12. 10889811 - Antibody libraries (2021-01-12),

13. 10882920 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2021-01-05),

14. 10196635 - Rationally designed, synthetic antibody libraries and uses therefor (2019-02-05),

15. 10189894 - Rationally designed, synthetic antibody libraries and uses therefor (2019-01-29),

Title: The Inventive Mind of Michael Feldhaus: Revolutionizing Cancer Treatment and Neurological Therapies

Introduction:

Michael Feldhaus, a prolific inventor based in Grantham, NH, is making waves in the fields of cancer treatment and neurological therapies with his groundbreaking innovations. With an impressive portfolio of 27 patents, Feldhaus is at the forefront of developing novel solutions for some of the most pressing healthcare challenges of our time.

Latest Patents:

Feldhaus' latest patents showcase his dedication to advancing medical science. His invention of BCMA antibodies for cancer and immune disorder treatment has the potential to revolutionize the way these conditions are managed. Additionally, his work on antibodies against BACE1 for neurological disease therapy offers new hope for patients suffering from such conditions.

Career Highlights:

Having worked at companies like Adimab, LLC and Merrimack Pharmaceuticals, Inc., Feldhaus has honed his expertise in the biotechnology and pharmaceutical industries. His contributions have not only earned him recognition within these organizations but have also garnered respect and admiration from his peers in the field.

Collaborations:

Throughout his career, Feldhaus has collaborated with esteemed professionals such as Ulrik Bjerl Nielsen and Maximiliano Vasquez. These partnerships have been instrumental in driving innovation and bringing cutting-edge solutions to fruition, further solidifying Feldhaus' reputation as a visionary inventor.

Conclusion:

Michael Feldhaus's passion for innovation and his relentless pursuit of excellence have positioned him as a trailblazer in the realm of healthcare technology. By leveraging his patents and collaborations, Feldhaus continues to make significant strides in improving patient outcomes and shaping the future of cancer treatment and neurological therapies.

This text is generated by artificial intelligence and may not be accurate.